BioSpace News Archive

Net sales were $793.9M in the third quarter, down 10.5%, or 10.6% on a constant-currency basis.

The Company is posting this press release and, additionally, results tables that will be referenced on its webcast to its Investor Relations website.

Third quarter record quarterly net sales of $1.20B, up 5.2% year-over-year, and up 2.2% on an organic basis.

Schrodinger and ShanghaiTech University will embark on joint research projects to solve challenging scientific problems in molecular recognition of the human body that can lead to co-discoveries.

Based on this double-blinded, placebo-controlled, multi-center study, data are presented from 93 subjects with bilateral knee OA who received 4 weekly doses of TPX-100 by intra-articular administration in one knee and identical placebo injections in the other, with at least one follow-up evaluation at 6 and 12 months.

Quark Pharmaceuticals announced that positive results from a Phase 2 clinical study on its lead program QPI-1002 will be presented as an oral abstract at the EuroTIDES conference being held in Vienna Austria November 7-10, 2017.

Ardelyx, today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017.

The Phase 2 dose-rising trial will evaluate the safety and preliminary efficacy of NanoPac delivered directly into MCNs by endoscopic ultrasound-guided fine needle injection.

The designation was based on direct feedback from hospital experts who interacted with LMA® Gastro™ Airway at the Vizient Innovative Technology Exchange in Denver on Sept. 14, 2017.

NovaBay announces that it will report third quarter 2017 financial results after market close on Tuesday, November 14.